What disease is dapostat used to treat?

Daprodustat (Daprodustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), mainly used to treat anemia associated with chronic kidney disease (CKD). Chronic kidney disease is a disease characterized by a gradual decline in kidney function, often accompanied by reduced red blood cell production, leading to anemia. The main reason is that the kidneys cannot effectively produce erythropoietin (EPO), and EPO is a key hormone that stimulates bone marrow hematopoiesis. Daprostat indirectly activates the HIF pathway by inhibiting prolyl hydroxylase in the body, causing the body to perceive it as being in a "hypoxic state", thereby increasing the production of endogenous EPO, while regulating the expression of other genes required for iron metabolism and erythropoiesis, thereby increasing hemoglobin levels.

Traditional treatment for CKD anemiaThe way to treat anemia in CKD is usually to inject exogenous EPO preparations (such as recombinant human erythropoietin). However, these treatments have problems such as poor compliance, inconvenient injection, and poor efficacy in some people. Daprostat, as a daily oral drug, has shown good efficacy in both dialysis and non-dialysis patients, and its mechanism of action is closer to the human body's endogenous hematopoietic regulatory system. According to overseas phase III clinical studies (such as ASCEND-ND and ASCEND-D), daprostat is not inferior to danakizumab (Darbepoetin alfa) in improving hemoglobin levels, and may have more advantages in terms of iron utilization efficiency and stability under inflammatory interference.

It is worth noting that daprostat has received regulatory approval in Japan, the European Union, the United Kingdom and the United States, and is suitable for dialysis and non-dialysis patients with chronic kidney disease, especially those who are ineffective or intolerant to traditional erythropoietin therapy. During use, it is necessary to monitor changes in hemoglobin and be alert to potential adverse reactions, including hypertension, thrombotic events and cardiovascular risks, although current relevant studies have not shown that its cardiovascular safety is better than traditional EPO preparations.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat